Donna Glover

2.2k total citations
38 papers, 1.8k citations indexed

About

Donna Glover is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Donna Glover has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Donna Glover's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). Donna Glover is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). Donna Glover collaborates with scholars based in United States, Switzerland and Italy. Donna Glover's co-authors include John H. Glick, Andrew T. Turrisi, Morton M. Kligerman, Kevin R. Fox, Clare Weiler, Joan E. Mollman, W. Michael Hogan, C Weiler, John M. Yuhas and Roy Furman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Donna Glover

37 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donna Glover United States 26 855 503 465 429 235 38 1.8k
N. H. Mulder Netherlands 25 1.1k 1.3× 285 0.6× 804 1.7× 365 0.9× 262 1.1× 69 2.5k
F. Ries Luxembourg 21 622 0.7× 108 0.2× 330 0.7× 325 0.8× 323 1.4× 70 1.7k
R. Brian Mitchell United States 11 478 0.6× 176 0.3× 518 1.1× 363 0.8× 160 0.7× 17 1.4k
M Forni France 19 1.1k 1.3× 112 0.2× 526 1.1× 458 1.1× 182 0.8× 39 1.8k
Felix E. de Jongh Netherlands 22 1.2k 1.4× 334 0.7× 250 0.5× 448 1.0× 262 1.1× 34 2.1k
Fabienne Thomas France 26 829 1.0× 130 0.3× 516 1.1× 332 0.8× 184 0.8× 109 2.0k
David Chu United States 27 1.1k 1.2× 140 0.3× 1.1k 2.3× 674 1.6× 171 0.7× 56 2.8k
Gregory D. Leonard United States 13 1.4k 1.6× 106 0.2× 517 1.1× 235 0.5× 188 0.8× 30 2.0k
Kyung Hwan Kim South Korea 26 994 1.2× 236 0.5× 429 0.9× 485 1.1× 145 0.6× 95 2.2k
Andrej Skerjanec Switzerland 19 669 0.8× 244 0.5× 705 1.5× 153 0.4× 129 0.5× 44 1.9k

Countries citing papers authored by Donna Glover

Since Specialization
Citations

This map shows the geographic impact of Donna Glover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Glover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Glover more than expected).

Fields of papers citing papers by Donna Glover

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna Glover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Glover. The network helps show where Donna Glover may publish in the future.

Co-authorship network of co-authors of Donna Glover

This figure shows the co-authorship network connecting the top 25 collaborators of Donna Glover. A scholar is included among the top collaborators of Donna Glover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna Glover. Donna Glover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Turrisi, Andrew T., Donna Glover, & Bernard A. Mason. (2015). Concurrent Twice-Daily Radiotherapy Plus Platinum-Etoposide Chemotherapy for the Treatment of Limited Small Cell Lung Cancer: A Preliminary Report. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 41. 109–114.
2.
Glover, Donna, Joseph G. Ibrahim, John M. Kirkwood, et al.. (2003). Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma. Melanoma Research. 13(6). 619–626. 31 indexed citations
3.
Gradishar, William J., Patricia Stephenson, Donna Glover, et al.. (2001). A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma. Cancer. 92(10). 2517–2522. 17 indexed citations
4.
Glover, Donna. (1998). Longitudinal Investigation of Candida Vaginitis in Pregnancy: Role of Superimposed Antibiotic Use. Obstetrics and Gynecology. 91(1). 115–118. 27 indexed citations
5.
Glover, Donna, et al.. (1994). Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer. 74(11). 2949–2955. 85 indexed citations
6.
Turrisi, Andrew T. & Donna Glover. (1990). Thoracic radiotherapy variables: Influence on local control in small cell lung cancer limited disease. International Journal of Radiation Oncology*Biology*Physics. 19(6). 1473–1479. 42 indexed citations
7.
Glover, Donna, et al.. (1989). Clinical trials of WR-2721 and cis-platinum. International Journal of Radiation Oncology*Biology*Physics. 16(5). 1201–1204. 50 indexed citations
8.
Glover, Donna, Kevin R. Fox, Clare Weiler, et al.. (1988). Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmacology & Therapeutics. 39(1-3). 3–7. 51 indexed citations
9.
Turrisi, Andrew T., Donna Glover, & Bernard A. Mason. (1988). A preliminary report: Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 15(1). 183–187. 106 indexed citations
10.
Shaw, Leslie M., Donna Glover, Andrew T. Turrisi, et al.. (1988). Pharmacokinetics of WR-2721. Pharmacology & Therapeutics. 39(1-3). 195–201. 70 indexed citations
11.
12.
Mollman, Joan E., Donna Glover, W. Michael Hogan, & Roy Furman. (1988). Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 61(11). 2192–2195. 172 indexed citations
13.
Mollman, Joan E., W. Michael Hogan, Donna Glover, & Leo McCluskey. (1988). Unusual presentation of cis‐platinum Neuropathy. Neurology. 38(3). 488–488. 44 indexed citations
14.
Glover, Donna & John H. Glick. (1987). Metabolic Oncologic Emergencies. CA A Cancer Journal for Clinicians. 37(5). 302–320. 14 indexed citations
15.
Glover, Donna, John H. Glick, C Weiler, Kevin R. Fox, & DuPont Guerry. (1987). WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.. Journal of Clinical Oncology. 5(4). 574–578. 151 indexed citations
16.
Glover, Donna, John H. Glick, Clare Weiler, et al.. (1986). Phase I/II trials of WR-2721 and cis-platinum. International Journal of Radiation Oncology*Biology*Physics. 12(8). 1509–1512. 89 indexed citations
17.
Glover, Donna, Donald L. Trump, Larry K. Kvols, Paul Elson, & Steven E. Vogl. (1986). Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. International Journal of Radiation Oncology*Biology*Physics. 12(8). 1405–1408. 16 indexed citations
18.
Glover, Donna, Louis J. Riley, Brian D. Spar, et al.. (1983). Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent). New England Journal of Medicine. 309(19). 1137–1141. 76 indexed citations
19.
Yuhas, John M., et al.. (1982). Circumvention of the tumor membrane barrier to WR-2721 absorption by reduction of drug hydrophilicity. International Journal of Radiation Oncology*Biology*Physics. 8(3-4). 519–522. 31 indexed citations
20.
Blumberg, Albert L., Diana F. Nelson, Donna Glover, et al.. (1982). Clinical trials of WR-2721 with radiation therapy. International Journal of Radiation Oncology*Biology*Physics. 8(3-4). 561–563. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. H. Mulder Breakdown of academic impact, for papers by F. Ries Breakdown of academic impact, for papers by R. Brian Mitchell Breakdown of academic impact, for papers by M Forni Breakdown of academic impact, for papers by Felix E. de Jongh Breakdown of academic impact, for papers by Fabienne Thomas Breakdown of academic impact, for papers by David Chu Breakdown of academic impact, for papers by Gregory D. Leonard Breakdown of academic impact, for papers by Kyung Hwan Kim Breakdown of academic impact, for papers by Andrej Skerjanec
Rankless by CCL
2026